Research comparison
Ipamorelin vs CJC-1295
Side-by-side comparison of research status, mechanisms, pharmacokinetics, and administration routes.
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist. Unlike other GHRPs, it stimulates GH release with high selectivity — producing minimal cortisol, ACTH, or prolactin elevation. It is among the most studied GHRPs for its clean GH pulse profile, making it a preferred research peptide for GH axis studies with reduced side effect concern.
Research Status
Preclinical Research
Half-Life
~2 hours
Molecular Formula
C₃₈H₄₉N₉O₅
Molecular Weight
711.86 Da
CAS Number
170851-70-4
Research Categories
Growth Hormone Axis
Routes of Administration
CJC-1295 is a modified GHRH analog with a Drug Affinity Complex (DAC) that binds to serum albumin, dramatically extending its half-life compared to native GHRH. It produces sustained elevation of GH and IGF-1 levels over days rather than hours. Research focuses on body composition improvements, muscle growth, and fat loss through prolonged GH axis stimulation.
Research Status
Preclinical Research
Half-Life
6–8 days (due to DAC albumin binding)
Molecular Formula
C₁₅₂H₂₅₂N₄₂O₄₂S
Molecular Weight
3647.28 Da
CAS Number
863288-34-0
Research Categories
Growth Hormone Axis
Routes of Administration
Full mechanism comparison
Mechanism of action, pharmacokinetics, and research findings comparison available on the Researcher plan.
Unlock full comparison →Related comparisons